Cargando…
Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guid...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155154/ https://www.ncbi.nlm.nih.gov/pubmed/25214921 |
Sumario: | BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors. METHODS: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history. RESULTS: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions. CONCLUSIONS: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment. |
---|